US Patent

US9089471 — Formulation of indomethacin

Method of Use · Assigned to Iceutica Pty Ltd · Expires 2030-04-23 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for producing indomethacin particles and compositions, as well as methods of treatment using a therapeutically effective amount of indomethacin.

USPTO Abstract

The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-55 — Indocin Sr
U-55 — Indocin Sr

Patent Metadata

Patent number
US9089471
Jurisdiction
US
Classification
Method of Use
Expires
2030-04-23
Drug substance claim
No
Drug product claim
No
Assignee
Iceutica Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.